Teva prepares to term out funding but opioid problems weigh on costs

Generic pharmaceuticals firm Teva has released price thoughts for a $1.5bn bond refinancing, which will term out its maturities. But the levels on offer show potential opioid litigation is still weighing on the firm’s capital structure. The Israeli company settled with a group of US states at the end of October, sending its shares and bonds surging, but the firm faces a trial in New York next March.